15 January 2020 - Recordati announces that the European Commission has granted marketing authorisation for the orphan medicinal product Isturisa (osilodrostat), indicated for the treatment of endogenous Cushing’s syndrome in adults. 

The active substance of Isturisa is osilodrostat, a cortisol synthesis inhibitor. Osilodrostat works by inhibiting 11‐beta‐hydroxylase, an enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. 

Isturisa will be available as 1 mg, 5 mg and 10 mg film‐coated tablets.

Read Recordati press release